布林佐胺联合噻吗洛尔治疗原发性开角型青光眼的有效性及安全性评价

Efficacy and safety of brinzolamide and timolol fixed combination to treat primary open- angle glaucoma

目的评价布林佐胺联合噻吗洛尔治疗原发性开角型青光眼的有效性和安全性。方法本研究采用大样本双盲随机对照研究,将入选原发性开角型青光眼患者,随机分为对照组(211例)和治疗组(212例),对照组给予噻吗洛尔进行治疗,治疗组给予噻吗洛尔和布林佐胺联合进行治疗,在第2、4、6、8、12周测量眼压、视力、血压和心率,观察眼部及全身不良反应情况,统计不良反应发生率。结果治疗组较对照组降眼压效果显著、不同时间波动范围小,不良反应发生率低。结论布林佐胺联合噻吗洛尔治疗原发性开角型青光眼临床安全性较高、患者耐受性好、价格低廉,可推广使用。

Objective To evaluate the efficacy and safety of brinzolamide and timolol fixed -combination therapy compared with timolol monotherapy in patients with primary open - angle glaucoma. Methods This study used large sample, double - blind, randomized, controlled study. The patients with primary open - angle glaucoma were randomly divided into control group（211 cases） and experimental group （212 cases）. Intraocular pressure, visual acuity, blood pressure and heart rate were observed and measured at 2, 4, 6,8,12 weeks. Adverse events （AEs） were recorded at each visit, and ultimately adverse effects rates were statistic. Results Mean intraocular pressure reductions from baseline were greater with experimental group than with control group, and intraocular pressure floated little in different time. The incidence of adverse reactions was less, and all adverse reactions were mild and moderate. Conclusions Brinzolamide and timolol fixed -combination therapy was associated with significantly greater reductions in primary open- angle glaucoma, was well tolerated in patient, maybe an effective and safe treatment.